Skip to main content

An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects with Eosinophilic Esophagitis

Office of Patient Recruitment

Do You Have Eosinophilic Esophagitis (EoE)?

A doctor examining a female patient's throat

A doctor examining a male patient's throat

Consider Research Study Evaluating Zemaira® for EoE

What is EoE?

Eosinophilic Esophagitis (EoE) is a chronic condition in which eosinophils, a type of white blood cell, build up in the esophagus.

Symptoms may include:

  • Difficulty swallowing
  • Chest or stomach pain
  • Vomiting
  • Sensation of food getting stuck in the throat

About This Study

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), led by Dr. Gregory Constantine, are evaluating the FDA-approved drug Zemaira® to determine its effectiveness in treating EoE.

Study Details:

  • Eligible participants will receive Zemaira® for 4 weeks
  • Total study participation may last up to 28 weeks
  • Compensation may be provided

Who Can Participate?

Are you looking for new treatment options? You may qualify if you:

  • Are 18 to 70 years old
  • Are willing to maintain your current dietary regimen

The NIH Clinical Center, America's Research Hospital, is located in Bethesda, MD on the Metro Red Line (Medical Center stop).

For more information:
NIH Clinical Center Office of Patient Recruitment
1-800-411-1222
TTY users dial 7-1-1
Email: ccopr@nih.gov

Or go online
Refer to NIH study # 001854-I

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Institute of Allergy and Infectious Diseases (NIAID)